Skip to main content

Table 3 Annual changes in WBC in relation to the FMP across baseline age subgroups a

From: Trajectories of peripheral white blood cells count around the menopause: a prospective cohort study

WBC indicators

Baseline age < 45 years

Baseline age ≥ 45 years

Obs. d

β (SE)

P Value

Obs. d

β (SE)

P Value

NEUT, ×109 /L

      

Time segments relative to FMP

A. < -5 y relative to FMP

2,918

0.010(0.012)

0.3748

685

-0.005(0.025)

0.8369

B. -5 -4 y relative to FMP

703

0.033(0.039)

0.3872

356

-0.054(0.057)

0.3471

C. -4  + 2 y relative to FMP

3,668

-0.087(0.010)

< 0.0001

4,113

-0.030 (0.010)

0.0020

D. +2  + 6 y relative to FMP

1,562

0.004(0.013)

0.7287

2,588

0.004(0.011)

0.7270

E. > +6 y relative to FMP

538

-0.015(0.025)

0.5424

2,504

0.022(0.010)

0.0338

LYM, ×109/L

      

Time segments relative to FMP

A. < -5 y relative to FMP

2,957

-0.019(0.005)

0.0003

690

-0.012(0.011)

0.2552

B. -5 -1 y relative to FMP

2,666

0.000(0.005)

0.9976

2,251

-0.021(0.006)

0.0008

C. > -1 y relative to FMP

3,861

0.009(0.004)

0.0426

7,397

0.002(0.004)

0.7191

MON, ×109/L

      

Time segments relative to FMP

A. < -4 y relative to FMP

3,614

-0.006(0.001)

< 0.0001

1,036

-0.016(0.004)

< 0.0001

B. -4  + 2 y relative to FMP

3,658

-0.001(0.001)

0.2648

4,105

-0.009(0.001)

< 0.0001

C. > +2 y relative to FMP

2,068

-0.000(0.001)

0.9775

5,034

0.004(0.001)

< 0.0001

  1. Abbreviations: WBC, white blood cells; NEUT, neutrophils; LYM, lymphocytes; MON, monocytes; Obs., observations; FMP, final menstrual period
  2. a Participants were divided into two baseline age subgroups: Those baseline age < 45 years and those ≥ 45 years. Women with at least 2 measurements for a given lipid parameter were included for mixed-effect models. Models were adjusted for age at checkup (continuous), educational level, smoking status, alcohol consumption, physical activity, hypertension history and anti-hypertensive medication, diabetes history and anti-diabetic medication, dyslipidemia history and lipid-lowering medication, body mass index (continuous), and hemoglobin (continuous) as fixed effects
  3. b Number of observations used to build models